Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

High-performing venture funds execute strict portfolio triage, refusing follow-on funding to underperforming companies regardless of past participation. Evenly distributing capital across all portfolio assets starves top-tier winners of the resources required to achieve critical clinical milestones.

Related Insights

For a seed fund, the initial check is less critical than subsequent follow-on decisions. Driving top-tier returns requires a reserve-heavy model to pile capital into the 5-10% of portfolio companies that demonstrate breakout potential, as these few winners will generate the lion's share of returns.

Unlike tech investing, where a single power-law outlier can return the entire fund, biotech wins are smaller in magnitude. This dynamic forces biotech VCs to prioritize a higher success rate across their portfolio rather than solely hunting for one massive unicorn.

Successful concentration isn't just about doubling down on winners. It's equally about avoiding the dispersion of capital and attention. This means resisting the industry bias to automatically do a pro-rata investment in a company just because another VC offered a higher valuation.

While a 1x return on Miro for its late-stage investors seems like a failure, it's a positive outcome in the late-stage venture model where capital preservation on underperformers is key. A fund's success relies on massive returns from a few winners, not on every investment being a multi-bagger.

The extreme power law in venture means a tiny fraction of firms drive nearly all returns. An LP who over-diversifies across 50-70 managers is essentially buying the index and guaranteeing average performance. To achieve top-tier returns, LPs must concentrate capital in the few proven, top-performing firms.

While biotech cannot easily replicate tech's rapid iteration cycles due to high costs and long feedback loops, it can adopt the capital efficiency model of tech seed investing. The strategy is to kill flawed projects quickly and cheaply, ensuring that when you lose, you lose small.

While it's easy to stop funding obviously failing companies, the most difficult decisions involve startups that are doing okay but are not on a trajectory for venture-scale returns. The emotional challenge for VCs is balancing their supportive, founder-friendly role with the tough-minded discipline required for their LPs.

Santé Ventures operates on the principle that a 40-50% loss ratio is inherent to early-stage biotech investing. Attempting to reduce this failure rate is seen as a sign of not taking enough risk. The core strategy is ensuring the winners are large enough to pay for all the losers.

Scientific failure is an acceptable risk in biotech, but failure from preventable errors like poor trial design, regulatory oversights, or market access neglect is not. A key role for a VC is to provide expertise to mitigate these “bad” reasons for failure, ensuring capital is spent testing the core scientific hypothesis, not on operational mistakes.

Founders may feel betrayed when early VCs sell shares, but it's often driven by fiduciary duty, not a loss of faith. To raise later funds (e.g., Fund IV/V), VCs must show LPs real cash returns (DPI). This forces them to take some money off the table, even from their best-performing companies.